Updates are available Correction dated 2024-05-24
Click to view Correction: https://doi.org/10.1038/s41586-024-07542-6
-
Authors
Kim, Yoojoong https://orcid.org/0000-0003-2881-6856
Gumpper, Ryan H.
Liu, Yongfeng https://orcid.org/0000-0002-8649-7892
Kocak, D. Dewran
Xiong, Yan
Cao, Can https://orcid.org/0000-0003-4017-741X
Deng, Zhijie
Krumm, Brian E. https://orcid.org/0000-0001-6039-4767
Jain, Manish K. https://orcid.org/0000-0001-8173-3326
Zhang, Shicheng https://orcid.org/0000-0002-5245-443X
Jin, Jian https://orcid.org/0000-0002-2387-3862
Roth, Bryan L. https://orcid.org/0000-0002-0561-6520
- License Information
-
More Information
Article History
Received: 26 October 2023
Accepted: 28 February 2024
First Online: 10 April 2024
Change Date: 24 May 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41586-024-07542-6
Competing interests
: J.J. is a co-founder and equity shareholder in Cullgen Inc., a scientific co-founder and scientific advisory board member of Onsero Therapeutics Inc., and a consultant for Cullgen Inc., EpiCypher Inc., Accent Therapeutics Inc. and TavotekBiotherapeutics Inc. The Jin laboratory received research funds from Celgene Corporation, Levo Therapeutics Inc., Cullgen Inc. and Cullinan Oncology Inc. B.L.R. is a co-founder of Onsero and Epiodyne and a scientific advisory board member of Escient Pharmaceuticals and Lassogen. University of North Carolina has licensed TRUPATH technology to many pharmaceutical and biotechnology companies.
